2-year survival data from a randomized study of peginterferon alfa-2a (40KD) vs interferon alfa-2a in patients with chronic-phase chronic myelogenous leukemia.

被引：0
|
作者：
Lipton, JH
Khoroshko, ND
Golenkov, AK
Abdulkadyrov, KM
Nair, MK
Raghunadharao, D
Brummendorf, T
Bergstrom, B
机构：
[1] Princess Margaret Hosp, Allogene BMT Program, Toronto, ON M4X 1K9, Canada
[2] Hematol Res Ctr, Dept Leucosis, Chemotherapy & Pathol Erithron, Moscow, Russia
[3] Moscow Regional Res Clin Inst, Dept Hematol Immunol, Moscow, Russia
[4] Russian Sci Res Inst Hematol & Transfusiol, Dept Hematol, St Petersburg, Russia
[5] Reg Canc Ctr, Dept Med Oncol, Trivandrum 695011, Kerala, India
[6] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad, Andhra Pradesh, India
[7] Univ Tubingen, Med Klin Poliklin, Dept Hematol Oncol Immunol & Rheumatol, Tubingen, Germany
[8] Hoffmann La Roche Inc, Nutley, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3363
引用
收藏
页码：904A / 904A
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
    Wirth, Stefan
    Zhang, Hongfei
    Hardikar, Winita
    Schwarz, Kathleen B.
    Sokal, Etienne
    Yang, Weibo
    Fan, Huimin
    Morozov, Vyacheslav
    Mao, Qing
    Deng, Hong
    Huang, Yang
    Yang, Lei
    Frey, Nicolas
    Nasmyth-Miller, Clare
    Pavlovic, Vedran
    Wat, Cynthia
    HEPATOLOGY, 2018, 68 (05) : 1681 - 1694
  • [32] Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B
    Mieli-Vergani, Giorgina
    Bansal, Sanjay
    Daniel, James F.
    Kansu, Aydan
    Kelly, Deirdre
    Martin, Carmen
    Tizzard, Sarah
    Wirth, Stefan
    Zhou, Julian
    Vergani, Diego
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 73 (02): : 156 - 160
  • [33] Peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)
    Fargion, S
    Borzio, M
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2003, 38 : 139 - 140
  • [34] Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
    Heathcote, EJ
    Shiffman, ML
    Cooksley, WGE
    Dusheiko, GM
    Lee, SS
    Balart, L
    Reindollar, R
    Reddy, RK
    Wright, TL
    Lin, A
    Hoffman, J
    De Pamphilis, J
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23): : 1673 - 1680
  • [35] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [36] INTERFERON ALFA-2A FOR CHRONIC MYELOID-LEUKEMIA - REPLY
    TURA, S
    BACCARANI, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (06): : 402 - 402
  • [37] The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    VALUE IN HEALTH, 2003, 6 (03) : 262 - 263
  • [38] Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity
    Brennan, Barbara J.
    Xu, Zhi-Xin
    Grippo, Joseph F.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 497 - 506
  • [39] Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD)
    Lee, SS
    Heathcote, EJ
    Reddy, KR
    Zeuzem, S
    Fried, MW
    Wright, TL
    Pockros, PJ
    Häussinger, D
    Smith, CI
    Lin, A
    Pappas, SC
    JOURNAL OF HEPATOLOGY, 2002, 37 (04) : 500 - 506
  • [40] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
12345